SUPERSTRING CAPITAL MANAGEMENT LP
Position in ANL — Adlai Nortye Group Ltd.
CIK 1931118
NEW YORK, NY
Position in ANL
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$6,353,761
+$3,482,986 QoQ
Shares Held
552,501
+33.2% QoQ
Ownership
0.858%
of shares outstanding
% of Portfolio
3.99%
of 13F equity value
Holder Rank
#14
of 42 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ANL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026SUPERSTRING CAPITAL MANAGEMENT LP holds $154,068,139 across 30 Biotechnology names. ANL ranks #12 (4.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | COGT |
Cogent Biosciences, Inc.
|
343,284 | $13,285,090 | |
| 2 | AXSM |
Axsome Therapeutics, Inc.
|
53,916 | $13,197,019 | |
| 3 | GMAB |
Genmab A/S
|
430,600 | $11,828,582 | |
| 4 | CLDX |
Celldex Therapeutics, Inc.
|
287,583 | $10,700,963 | |
| 5 | TRVI |
Trevi Therapeutics, Inc.
|
524,224 | $9,776,777 | |
| 6 | RVMD |
Revolution Medicines, Inc.
|
51,053 | $9,561,205 | |
| 7 | DFTX |
Definium Therapeutics, Inc.
|
188,282 | $8,856,785 | |
| 8 | VIR |
Vir Biotechnology, Inc.
|
853,685 | $8,699,050 |
All Filings in ANL
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $6,353,761 | 552,501 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $2,870,775 | 414,852 | Shares | Sole | 2026-05-14 | |
| No filing history on record for this holder in this stock. | ||||||